| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/25/2002 | EP1242436A2 Oligosaccharide mixture |
| 09/25/2002 | EP1242435A2 Medicaments for treatment of respiratory syncytial virus infections |
| 09/25/2002 | EP1242432A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 09/25/2002 | EP1242431A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 09/25/2002 | EP1242427A1 Novel piperidine and piperazine derivatives |
| 09/25/2002 | EP1242426A1 Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors |
| 09/25/2002 | EP1242423A1 SUBSTITUTED 1,2,3-TRIAZOLO 1,5-a]QUINAZOLINES FOR ENHANCING COGNITION |
| 09/25/2002 | EP1242422A1 Tricyclic dihydropyrimidine potassium channel openers |
| 09/25/2002 | EP1242421A1 4-[aryl(8-azabicyclo[3.2.1] octan-3-yl)] aminobenzoic acid derivatives |
| 09/25/2002 | EP1242418A1 Antidiabetic thiazolidinediones and their preparation |
| 09/25/2002 | EP1242417A1 Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
| 09/25/2002 | EP1242416A1 Substituted isoxazolines and their use as antibacterial agents |
| 09/25/2002 | EP1242415A1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242414A1 Pyrazolyl benzyl ethers |
| 09/25/2002 | EP1242413A1 Substituted 1,3,4-oxadiazoles and a method of reducing tnf-alpha levels |
| 09/25/2002 | EP1242410A1 Novel compounds |
| 09/25/2002 | EP1242409A2 Substituted bisindolylmaleimides |
| 09/25/2002 | EP1242408A1 Substituted bisindolylmaleimides for the inhibition of cell proliferation |
| 09/25/2002 | EP1242407A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242406A1 Novel compounds |
| 09/25/2002 | EP1242404A1 Phenoxypropanolamines, preparation and therapeutic use thereof |
| 09/25/2002 | EP1242403A1 2,4-diaminopyrimidine compounds usful as immunosuppressants |
| 09/25/2002 | EP1242402A2 Novel compounds |
| 09/25/2002 | EP1242401A1 Cytotoxic agents comprising taxanes and their therapeutic use |
| 09/25/2002 | EP1242400A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242399A1 $g(a)-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS |
| 09/25/2002 | EP1242398A2 Partially saturated calcium channel blockers |
| 09/25/2002 | EP1242397A1 Trans olefinic glucokinase activators |
| 09/25/2002 | EP1242396A1 New p2x 7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 09/25/2002 | EP1242395A1 Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent |
| 09/25/2002 | EP1242394A1 Novel 3-oxo-2,1-benzisoxazol-1(3h)-carboxamides for treatment of cns diseases |
| 09/25/2002 | EP1242389A2 Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them |
| 09/25/2002 | EP1242388A1 Method for production of a triazolinethione derivative |
| 09/25/2002 | EP1242385A1 Cytokine, especially tnf-alpha, inhibitors |
| 09/25/2002 | EP1242383A1 Aza compounds having neuronal activity |
| 09/25/2002 | EP1242382A1 Tricyclic protein kinase inhibitors |
| 09/25/2002 | EP1242381A2 2-phenyl-quinoline derivatives, preparation method and therapeutic use thereof |
| 09/25/2002 | EP1242379A1 Curcumin analogues for treating cancer |
| 09/25/2002 | EP1242378A1 Novel processes |
| 09/25/2002 | EP1242374A1 Acryloyl peptidic derivatives, process for their preparation and their use as antitumor agents |
| 09/25/2002 | EP1242372A1 Inhibitors of farnesyl protein transferase |
| 09/25/2002 | EP1242371A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242367A1 2-[3-amino-4-(n-hydroxyamino)-succinylamino-acetamides for use as cd23 formation inhibitors |
| 09/25/2002 | EP1242365A1 Acyl pseudodipeptides which carry a functionalised auxiliary arm |
| 09/25/2002 | EP1242364A1 Adamantane derivatives |
| 09/25/2002 | EP1242363A2 Cd45 inhibitors |
| 09/25/2002 | EP1242307A1 Method for preparing ortho silicic acid, ortho silicic acid as obtained, and its use |
| 09/25/2002 | EP1242123A2 Absorbing fat with chitosan |
| 09/25/2002 | EP1242119A2 Combinations for the treatment of dna viral infections comprising a loop diuretic and a cardiac glycoside |
| 09/25/2002 | EP1242110A1 A method and composition for treating prostate cancer |
| 09/25/2002 | EP1242106A1 Carbon dioxide enhancement of inhalation therapy |
| 09/25/2002 | EP1242105A2 Combination of ginseng and ginkgo to improve cognitive skills |
| 09/25/2002 | EP1242097A2 Pharmaceutical composition comprising a vanadium compound and at least a component selected from a na+/h+ exchanger, cyclo-oxygenase inhibitors and caspase inhibitors |
| 09/25/2002 | EP1242096A2 Combinations for the treatment of dna viral infections comprising a loop diuretic and lithium |
| 09/25/2002 | EP1242095A1 Antimicrobial compositions and methods of use |
| 09/25/2002 | EP1242094A1 Methods for treating mild cognitive impairment |
| 09/25/2002 | EP1242093A1 A method of treating substance addiction |
| 09/25/2002 | EP1242092A2 Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug |
| 09/25/2002 | EP1242091A2 Pharmaceutical compositions comprising oxcarbazepine |
| 09/25/2002 | EP1242090A1 Use of h1 antagonist and a safe steroid to treat eye conditions |
| 09/25/2002 | EP1242089A2 Use of adatanserin for the treatment of neurodegenerative conditions |
| 09/25/2002 | EP1242088A1 Oral mucosal dosage forms of apomorphine |
| 09/25/2002 | EP1242087A2 Analgesic compositions containing buprenorphine |
| 09/25/2002 | EP1242086A2 Cd45 inhibitors |
| 09/25/2002 | EP1242085A1 Benzimidazole compounds having nociceptin receptor affinity |
| 09/25/2002 | EP1242084A1 Treatment of lymphomas, leukemias, breast carcinomas, astrocytomas, melanomas, leiomyomas, and related tumors |
| 09/25/2002 | EP1242083A1 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them |
| 09/25/2002 | EP1242082A1 Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders |
| 09/25/2002 | EP1242081A1 Caspases and apoptosis |
| 09/25/2002 | EP1242079A1 Methods of use of fluoroquinolone compounds againts bacteria |
| 09/25/2002 | EP1242078A2 Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats |
| 09/25/2002 | EP1242077A1 Novel processes for making- and a new crystalline form of- leflunomide |
| 09/25/2002 | EP1242076A1 2-benzyl and 2-heteroaryl benzimidazole nmda/nr2b antagonists |
| 09/25/2002 | EP1242075A2 Indole compounds |
| 09/25/2002 | EP1242074A1 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline nmda/nr2b antagonists |
| 09/25/2002 | EP1242073A2 Compositions for prevention and treatment of cold and influenza-like symptoms and their methods of use |
| 09/25/2002 | EP1242072A1 Antipsychotic heterocycle compounds |
| 09/25/2002 | EP1242071A1 Use of parthenolide to inhibit cancer |
| 09/25/2002 | EP1242070A2 Treatment of ischemic brain injuries with brain targetted antioxidant compounds |
| 09/25/2002 | EP1242069A2 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 09/25/2002 | EP1242068A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 09/25/2002 | EP1242067A2 Calcium formate for use as a phosphorus binder and a dietary supplement |
| 09/25/2002 | EP1242066A1 Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
| 09/25/2002 | EP1242065A1 New combination comprising a beta 2 (beta)2 adreno receptor agonist and a leukotriene receptor antagonist |
| 09/25/2002 | EP1242064A1 Liver selective therapy |
| 09/25/2002 | EP1242063A1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 09/25/2002 | EP1242062A2 Anhydrous gel comprising nsaid for topical administration to the oral cavity |
| 09/25/2002 | EP1242061A2 Use of bioactive metabolites of gepirone for the treatment of psychological disorders |
| 09/25/2002 | EP1242059A2 Novel prodrugs for antimicrobial amidines |
| 09/25/2002 | EP1242058A1 Use of cyp2d6 inhibitors in combination therapies |
| 09/25/2002 | EP1242057A2 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 09/25/2002 | EP1242053A1 Apparatus and method for preparing microparticles using in-line solvent extraction |
| 09/25/2002 | EP1242051A1 Novel forms of pravastatin sodium |
| 09/25/2002 | EP1242050A2 Survivin promotion of angiogenesis |
| 09/25/2002 | EP1242048A1 Inhalation particles |
| 09/25/2002 | EP1242012A1 Improved transdermal contraceptive delivery system and process |
| 09/25/2002 | EP1242009A1 Tissue sensitizing compounds for females with methods and apparatus for the delivery of these compounds |
| 09/25/2002 | EP1241943A1 Use of polysiloxanes containing quaternary amino groups as formulation auxiliary agents, and agents containing the same |
| 09/25/2002 | EP1189610A4 Method and markers for prognosticating efficacy of anticancer agents |
| 09/25/2002 | EP1175432A4 Processes for the synthesis of oligomers using phosphoramidite compositions |